Design and application of HSV vectors for neuroprotection

Gene Therapy

Volumn 7, Issue 2, 2000, Pages 115-119

  Fink, D J ^a   DeLuca, N A ^a   Yamada, M ^a   Wolfe, D P ^a   Glorioso, J C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Gene transfer; Herpes simplex; Nerve growth factor; Neurodegenerative disease

Indexed keywords

NERVE GROWTH FACTOR; PROTEIN BCL 2; VIRUS DNA; VIRUS VECTOR;

APOPTOSIS; CELL DEATH; DNA MODIFICATION; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS GENE; VIRUS RECOMBINANT;

EID: 0033975511     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301118     Document Type: Short Survey

References (20)

1. Fink D et al. Gene transfer to neurons using herpes simplex virus-based vectors. Ann Rev Neurosci 1996; 19: 265-287.
2. Roizman B, Sears A. Herpes simplex viruses and their replication. In: Fields BN et al (eds). Fields Virology, vol. 2. Raven Press: Philadelphia, 1996, pp 2231-2295.
3. Herold B et al. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulfate and glycoprotein B. J Gen Virol 1994; 75: 1211-1222.
4. Tal-Singer R et al. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 1995; 69: 4471-4483.
5. Montgomery RI et al. Herpes simplex virus 1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
6. Geraghty RJ et al. Entry of alpha herpes viruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998; 280: 1618-1620.
7. Dixon RAF, Schaffer PA. Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol 1980; 36: 189-203.
8. Preston C. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 1979; 29: 275-284.
9. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
10. Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998; 72: 3307-3320.
11. Wu N et al. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol 1996; 70: 6358-6368.
12. Hobbs W, DeLuca N. Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICPO. J Virol 1999; 73: 8245-8255.
13. Wrzoa H, Rapp F. Establishment of latency in vitro with herpes simplex virus temperature-sensitive mutants at nonpermissive temperature. Virus Res 1987; 8: 301-308.
14. Spivack JG, Fraser NW. Detection of herpes simplex virus type 1 transcripts during latent infection in mice. J Virol 1987; 61: 3841-3847.
15. Spivack J, Fraser N. Expression of herpes simplex virus type 1 latency-associated transcripts in trigeminal ganglia of mice during acute infection and reactivation of latent infection. J Virol 1988; 62: 1479-1485.
16. Ramakrishnan R et al. Competitive quantitative polymerase chain reaction (PCR) analysis of herpes simplex virus type 1 DNA and LAT RNA in latently infected cells of the rat brain. J Virol 1994; 68: 1864-1870.
17. Ramakrishnan R et al. Detection of herpes simplex virus type 1 latency-associated transcript expression in trigeminal ganglia by in situ reverse transcriptase PCR. J Virol 1996; 70: 6519-6523.
18. Goins WF et al. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglia neurons from peroxide toxicity. J Virol 1999; 73: 519-532.
19. Wolfe DP et al. Long term systemic delivery of nerve growth factor for treatment of peripheral neuropathies using replication defective genomic HSV vectors. Soc Neurosci Abstr 1999; 25: 2279.
20. Yamada M et al. HSV vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999; 96: 4078-4083.